ITCI Stock Overview
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ITCI from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Intra-Cellular Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$55.73 |
| 52 Week High | US$66.00 |
| 52 Week Low | US$42.01 |
| Beta | 1.13 |
| 1 Month Change | 14.74% |
| 3 Month Change | 4.09% |
| 1 Year Change | -7.61% |
| 3 Year Change | 285.41% |
| 5 Year Change | 179.49% |
| Change since IPO | 457.30% |
Recent News & Updates
Recent updates
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Dec 24Intra-Cellular's Second FDA Win Makes It A Great Long-Term Investment
Dec 21Intra-Cellular Therapies: A Leader In The Psychiatric Medicine Space
Nov 08We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Aug 06We Think The Compensation For Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Looks About Right
Jun 15Intra-Cellular Therapies (ITCI) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow
Jun 04FDA accepts Intra-Cellular Therapies' lumateperone applications for bipolar depression
May 03We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Mar 23The Intra-Cellular Therapies (NASDAQ:ITCI) Share Price Is Up 99% And Shareholders Are Holding On
Feb 16Have Insiders Been Selling Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares?
Jan 12
Intra-Cellular Therapies launches clinical trials for treatment of schizophrenia and opioid use disorder
Dec 29The Play On Intra-Cellular Therapies Now
Dec 20Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Dec 08Intra-Cellular Therapies: Another Growth Cycle Approaching
Dec 04Intra-Cellular Therapies (ITCI) Investor Presentation - Slideshow
Nov 16Intra-Cellular Therapies EPS beats by $0.20, beats on revenue
Nov 09Shareholder Returns
| ITCI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 22.2% | 1.2% | 0.9% |
| 1Y | -7.6% | -6.3% | -16.0% |
Return vs Industry: ITCI underperformed the US Pharmaceuticals industry which returned -5.5% over the past year.
Return vs Market: ITCI exceeded the US Market which returned -15.5% over the past year.
Price Volatility
| ITCI volatility | |
|---|---|
| ITCI Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ITCI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ITCI's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 561 | Sharon Mates | https://www.intracellulartherapies.com |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.
Intra-Cellular Therapies, Inc. Fundamentals Summary
| ITCI fundamental statistics | |
|---|---|
| Market Cap | US$5.31b |
| Earnings (TTM) | -US$256.26m |
| Revenue (TTM) | US$250.31m |
21.2x
P/S Ratio-20.7x
P/E RatioIs ITCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITCI income statement (TTM) | |
|---|---|
| Revenue | US$250.31m |
| Cost of Revenue | US$155.16m |
| Gross Profit | US$95.16m |
| Other Expenses | US$351.41m |
| Earnings | -US$256.26m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.69 |
| Gross Margin | 38.01% |
| Net Profit Margin | -102.37% |
| Debt/Equity Ratio | 0% |
How did ITCI perform over the long term?
See historical performance and comparison